A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

OBJECTIVE: The proportion of patients with stage I lung adenocarcinoma (LUAD) has dramatically increased with the prevalence of low-dose computed tomography use for screening. Up to 30% of patients with stage I LUAD experience recurrence within 5 years after curative surgery. A robust risk stratific...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chengming, Wang, Sihui, Zheng, Sufei, Wang, Xinfeng, Huang, Jianbin, Lei, Yuanyuan, Mao, Shuangshuang, Feng, Xiaoli, Sun, Nan, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330534/
https://www.ncbi.nlm.nih.gov/pubmed/33856140
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330534/
https://www.ncbi.nlm.nih.gov/pubmed/33856140
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0397

Ejemplares similares